HRAS

Across TCGA pan-cancer cohorts, HRAS Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated HRAS data layer compared with 27 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher HRAS Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HRAS expression acts as an unfavorable survival marker.

BRCA and THCA are the cancer types where HRAS Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	III,IV	0.176	0.833	<.001	20	view →
THCA	DFS	Median	IV	0.075	0.807	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

HRAS–BRCA (OS)

Open the BRCA breakdown →